Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms

Fc Engineering to Improve the Function of Therapeutic Antibodies

(2016) Futa Mimoto et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Half-life extended biotherapeutics

(2016) Roland E. Kontermann   EXPERT OPINION ON BIOLOGICAL THERAPY

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

(2016) Christian Klein et al.   mAbs

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

(2016) João Pedro Martins et al.   PHARMACOLOGY & THERAPEUTICS

Coming-of-Age of Antibodies in Cancer Therapeutics

(2016) B. Vijayalakshmi Ayyar et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions

(2015) Algirdas Grevys et al.   JOURNAL OF IMMUNOLOGY

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies

(2015) Amita Datta-Mannan et al.   mAbs

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

(2015) Amita Datta-Mannan et al.   mAbs

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity

(2015) Yasmina Noubia Abdiche et al.   mAbs

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life

(2015) Colby A Souders et al.   mAbs

Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics

(2015) Kine Marita Knudsen Sand et al.   Frontiers in Immunology

Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

(2014) Bing Li et al.   mAbs

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics

(2013) Craig Giragossian et al.   CURRENT DRUG METABOLISM

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies

(2013) Tilman Schlothauer et al.   mAbs

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

A strategy for risk mitigation of antibodies with fast clearance

(2012) Isidro Hötzel et al.   mAbs

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

(2011) Jennifer Q. Dong et al.   CLINICAL PHARMACOKINETICS

Neonatal Fc receptor and IgG-based therapeutics

(2011) Timothy T. Kuo et al.   mAbs

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

Engineering the variable region of therapeutic IgG antibodies

(2011) Tomoyuki Igawa et al.   mAbs

Antibody fragments

(2010) Aaron L. Nelson   mAbs

Reduced elimination of IgG antibodies by engineering the variable region

(2010) T. Igawa et al.   PROTEIN ENGINEERING DESIGN & SELECTION